Leerink Partners Maintains Outperform on CVS Health, Lowers Price Target to $104

Benzinga · 15h ago
Leerink Partners analyst Michael Cherny maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $112 to $104.